Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
13.39 USD +3.08% Intraday chart for NeuroPace, Inc. -4.22% +29.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Inflation -2- DJ
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16 MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating MT
NeuroPace Shares Decline Following Q4 Financial Results MT
NeuroPace, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NeuroPace, Inc., Q4 2023 Earnings Call, Mar 05, 2024
NeuroPace, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M MT
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024 CI
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating MT
NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary CI
Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target MT
Transcript : NeuroPace, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
NeuroPace Preliminary Q4 Revenue Beats Street View; Shares Rise MT
NeuroPace, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended December 31, 2023 CI
NeuroPace, Inc. Revises Revenue Guidance for the Full Year 2023 CI
NeuroPace, Inc. Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study CI
NeuroPace, Inc. to Leverage the Power of its RNS System?s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration CI
Morgan Stanley Adjusts NeuroPace Price Target to $9 From $8, Maintains Equal Weight Rating MT
Morgan Stanley Adjusts Price Target on NeuroPace to $8 From $6, Maintains Equalweight Rating MT
Cantor Fitzgerald Starts Coverage on NeuroPace with Overweight Rating, $11 Price Target MT
NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : NeuroPace, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Earnings Flash (NPCE) NEUROPACE Reports Q3 Revenue $16.4M, vs. Street Est of $14.2M MT
Wells Fargo Adjusts NeuroPace Price Target to $9 From $6, Maintains Equal Weight Rating MT
Chart NeuroPace, Inc.
More charts
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.39 USD
Average target price
17.71 USD
Spread / Average Target
+32.29%
Consensus
  1. Stock Market
  2. Equities
  3. NPCE Stock
  4. News NeuroPace, Inc.
  5. Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target